Atossa Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview

Atossa Therapeutics

04/11/2023 03:01

* Atossa Therapeutics Inc  ATOS.OQ   ATOS.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Atossa Therapeutics
Inc
is for a loss of 7 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atossa
Therapeutics Inc is $5.25​, above​ its last closing price
of $0.70. ​​​

This summary was machine generated November 4 at 03:01 GMT.  All
figures in US dollars  unless otherwise stated